Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial. weiter …

Source:: https://www.sciencedaily.com/releases/2018/04/180416101413.htm

Kommentar verfassen